AU622614B2 - Improvements in or relating to organic compounds - Google Patents

Improvements in or relating to organic compounds Download PDF

Info

Publication number
AU622614B2
AU622614B2 AU15605/88A AU1560588A AU622614B2 AU 622614 B2 AU622614 B2 AU 622614B2 AU 15605/88 A AU15605/88 A AU 15605/88A AU 1560588 A AU1560588 A AU 1560588A AU 622614 B2 AU622614 B2 AU 622614B2
Authority
AU
Australia
Prior art keywords
day
smoking
milligrams
bromocriptine
tobacco
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU15605/88A
Other languages
English (en)
Other versions
AU1560588A (en
Inventor
Peter S. Mueller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU1560588A publication Critical patent/AU1560588A/en
Assigned to MUELLER, PETER S. reassignment MUELLER, PETER S. Alteration of Name(s) of Applicant(s) under S113 Assignors: SANDOZ LTD.
Application granted granted Critical
Publication of AU622614B2 publication Critical patent/AU622614B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU15605/88A 1987-05-07 1988-05-05 Improvements in or relating to organic compounds Expired - Fee Related AU622614B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4775387A 1987-05-07 1987-05-07
US047753 1987-05-07

Publications (2)

Publication Number Publication Date
AU1560588A AU1560588A (en) 1988-11-10
AU622614B2 true AU622614B2 (en) 1992-04-16

Family

ID=21950776

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15605/88A Expired - Fee Related AU622614B2 (en) 1987-05-07 1988-05-05 Improvements in or relating to organic compounds

Country Status (13)

Country Link
JP (1) JPS63287723A (enExample)
KR (1) KR880013556A (enExample)
AU (1) AU622614B2 (enExample)
CH (1) CH675834A5 (enExample)
DE (1) DE3814521A1 (enExample)
DK (1) DK245388A (enExample)
FR (1) FR2614789B1 (enExample)
GB (1) GB2204240B (enExample)
IT (1) IT1219564B (enExample)
NL (1) NL8801171A (enExample)
PH (1) PH25495A (enExample)
SE (1) SE8801708L (enExample)
ZA (1) ZA883237B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797405A (en) * 1987-10-26 1989-01-10 Eli Lilly And Company Stabilized pergolide compositions
DE19626621A1 (de) * 1996-07-02 1998-01-08 Hexal Ag Pflaster zur transdermalen Anwendung von Pergolid
US6623752B1 (en) 1996-07-02 2003-09-23 Hexal Ag Patch for transdermal application for pergolid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7558787A (en) * 1986-07-14 1988-01-21 Sandoz Ltd. Improvements in or relating to organic compounds
AU591120B2 (en) * 1985-05-06 1989-11-30 Sandoz Ltd. Treatment of psychostimulant addiction using a dopamine agonist

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU591120B2 (en) * 1985-05-06 1989-11-30 Sandoz Ltd. Treatment of psychostimulant addiction using a dopamine agonist
AU7558787A (en) * 1986-07-14 1988-01-21 Sandoz Ltd. Improvements in or relating to organic compounds

Also Published As

Publication number Publication date
SE8801708L (sv) 1988-11-08
FR2614789B1 (fr) 1991-10-18
SE8801708D0 (sv) 1988-05-05
ZA883237B (en) 1990-01-31
NL8801171A (nl) 1988-12-01
KR880013556A (ko) 1988-12-21
DK245388D0 (da) 1988-05-05
DK245388A (da) 1988-11-08
GB8810509D0 (en) 1988-06-08
IT1219564B (it) 1990-05-18
AU1560588A (en) 1988-11-10
GB2204240A (en) 1988-11-09
CH675834A5 (enExample) 1990-11-15
GB2204240B (en) 1991-04-24
FR2614789A1 (fr) 1988-11-10
IT8847906A0 (it) 1988-05-03
PH25495A (en) 1991-07-24
DE3814521A1 (de) 1988-11-17
JPS63287723A (ja) 1988-11-24

Similar Documents

Publication Publication Date Title
US4800204A (en) Method of controlling tobacco use
US4935429A (en) Method of treating psychostimulant addiction
Rose et al. Nicotine–mecamylamine treatment for smoking cessation: The role of pre-cessation therapy.
Rose et al. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone
US5872145A (en) Formulation of 5-HT agonist and NSAID for treatment of migraine
US5152994A (en) Rapid method for interrupting or attenuating poly-drug dependency syndromes
US20020019421A1 (en) Compositions and therapy for substance addiction
Gourlay et al. Antismoking products
WO2003045437A8 (en) Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
US5480651A (en) Composition and method for treating nicotine craving in smoking cessation
Li Wan Po Transdermal nicotine in smoking cessation: A meta-analysis
Reisinger Buprenorphine as new treatment for heroin dependence
US5852032A (en) Method of treating nicotine dependence
Davidson et al. Bupropion sustained release: a therapeutic overview
PL196334B1 (pl) Zastosowanie agonistów receptorów GABA B i ich farmaceutycznie dopuszczalnych pochodnych w terapii abstynencji nikotynowej u uzależnionych od nikotyny pacjentów
AU622614B2 (en) Improvements in or relating to organic compounds
KR20020075795A (ko) 흡연을 감소시키거나 또는 제거하는 방법
WO1990000896A1 (en) USE OF BENZO(g)QUINOLINES IN TREATMENT OF NICOTINE ADDICTION
EP0204954B1 (en) Use of dopamine agonists for the manufacture of a medicament for the treatment of psychostimulant addiction
US20020168403A1 (en) Compositions and therapy for substance addiction
WO1995011679A1 (en) Use of lobeline for the treatment of nicotine withdrawal
Nørregaard et al. Long-term nicotine substitution after application of a 16-hour nicotine patch in smoking cessation
JPH07505367A (ja) 喫煙停止におけるニコチン渇望の処置のための副交感神経作用剤とムスカリン性拮抗剤との配合
EA004718B1 (ru) Способ сокращения или прекращения курения
Ussher et al. Diurnal variations in first lapses to smoking for nicotine patch users